News

Eyetech Inc. plans to use a $245,000 federal grant in its efforts to develop an extended-release formulation of pegaptanib sodium injection (Macugen) using microparticles technology.

The FDA has granted 3 years of marketing exclusivity to the U.S. marketer of the once-daily formulation of 0.09% bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals).

Optos plc plans to acquire the entire issued share capital of Opto Global Holdings Pty Ltd for up to $14.75 million.

The FDA has given 510(k) clearance to a non-mydriatic retinal camera (CR-2, Canon U.S.A.).

The FDA has approved a new biometer (IOLMaster 500, Carl Zeiss Meditec) to calculate eye measurements for lens selection related to cataract surgery.

The American National Standards Institute Z80 Accredited Standards Committee for Ophthalmic Optics has announced a new standard for toric IOLs.

Alcon Laboratories announced that it received clearance from the FDA to complete its voluntary medical device corrective action plan on its proprietary vitreoretinal system (Constellation Vision System) in the United States.

Historically, surgeons performed phacoemulsification with a straight-tip handpiece.

Want to jazz up your office and make a little extra profit at the same time? Read on.

Expert discusses the ways in which the AAO can help ophthalmologists survive and thrive in an uncertain economy.

The results of the 2010 Ophthalmology Times Best Programs survey show very few differences from last year despite advances and growth within ophthalmology departments across the United States.

If accessories are not part of your sales strategy, it's time to revisit that decision and explore the myths and realities of this category.

Results from a series of bench studies conducted under strictly controlled conditions consistently indicate that torsional phacoemulsification generates less heat at the incision site than longitudinal phaco.

The author discusses how policies can get in the way of good medicine.

Ongoing development of increasingly customized IOLs provides an ophthalmic surgeon with the means to offer refractive cataract surgery patients a lens or a combination of complementary lenses that specifically address their individual needs.

Some patients who have had previous wavefront-optimized laser vision correction present with quality-of-vision complaints, such as halo and glare, despite having 20/20 visual acuity.

Bilateral implantation of a three-piece aspheric diffractive multifocal IOL with refractive enhancement as needed provides excellent visual outcomes for a broad range of patients seen in real-world clinical practice.

A study evaluating outcomes in eyes undergoing LASIK for >-4 D of myopia reaffirms the established efficacy, safety and predictability of treatments performed with the wavefront-optimized, wavefront-guided and topography-guided ablation profiles of an excimer laser.

Throughout the eye department at Duke, faculty, residents, fellows and scientists work to further the understanding of eye disease and discover potential treatments.

Patients who have undergone cataract surgery with the +3-D add version of the apodized diffractive aspheric multifocal IOL implanted bilaterally demonstrate a significant postoperative improvement in perceived driving ability.

Providing appropriate amount of care to each patient is important.

The American Medical Association (AMA) has published a new Current Procedural Terminology (CPT) code that applies to a proprietary osmolarity test (TearLab).

Eyetech Inc. has entered into a licensing and development agreement with SurModics Pharmaceuticals Inc. to develop an extended-release version of pegaptanib sodium injection (Macugen) using microparticle technology.

The FDA has cleared a new, age-adjusted retinal nerve fiber layer thickness normative database for a proprietary ocular coherence tomography (OCT) device (Spectralis, Heidelberg Engineering GmbH).

The FDA has approved a supplemental new drug application for a once-daily bromfenac 0.09% ophthalmic solution (Bromday [formerly called XiDay], ISTA Pharmaceuticals) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

The FDA has cleared a new-generation multipurpose disinfecting solution (RevitaLens Ocutec, Abbott Medical Optics [AMO]) for silicone hydrogel and conventional soft contact lenses.

A new lubricant eye drop (Systane Balance, Alcon Laboratories) has been launched for patients with meibomian gland dysfunction.

About 23,000 people attended this year?s American Academy of Ophthalmology (AAO) annual meeting in Chicago, according to the organization.

A new lubricant eye drop offers a new treatment option for patients with meibomian gland dysfunction.

A dexamethasone intravitreal implant is a notable new therapeutic option for eyes with macular edema secondary to branch retinal vein occlusion or central retinal vein occlusion and may reduce the risk of vision loss as well as improve both the speed and incidence of visual improvement, according to one expert.